Breast cancer survivors who underwent chemotherapy or hormone therapy were found to be more likely to have a higher symptom burden and lower overall sense of well-being than noncancer counterparts.
An analysis of the results of the phase III PANTHER trial showed that a combination of tailored dose-dense adjuvant chemotherapy and trastuzumab decreased the relative risk of relapse for patients with HER2-positive breast cancer.
These results could present an opportunity to broaden inclusion criteria on clinical trials and intensify chemoradiotherapy treatments.
Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma.
A phase I study showed brentuximab vedotin combined with a standard chemotherapy regimen of mitoxantrone, etoposide, and cytarabine may be safe and well tolerated in patients with relapsed/refractory acute myeloid leukemia.
The Willamette Valley Cancer Institute and Research Center expert talks about the results of the ELEVATE TN trial at the ASH Annual Meeting and Exposition.
The Ohio State University Comprehensive Cancer Center expert discussed the ongoing Alliance A041702 trial at the ASH Annual Meeting and Exposition.
The expert hematologist from Plymouth University Medical Center discussed the long-term outcomes of patients receiving ibrutinib for mantle cell lymphoma at the ASH Annual Meeting and Exposition.
In our lung cancer quiz, you'll get a chance to test your knowledge of the mortality risk among patients with lung cancer, and learn more about screening criteria to try reduce these rates.
The recommendations defined when and how radiation therapy should be used to treat patients with basal cell carcinoma and cutaneous squamous cell carcinoma.
A recent study shows the importance of information regarding adverse events of cancer treatment for prospective patients.
When treatment decisions were made using a prostate genomic classifier after radical prostatectomy in men with prostate cancer, patient outcomes significantly improved.
The FDA approved olaparib for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma.
The use of common heart drugs in conjunction with cancer therapy led to reduced cardiotoxicity in patients with breast and hematological cancers.
Bijal D. Shah, MD, discusses the progress made regarding CAR T-cell therapy and mantle cell lymphoma.